Comella, P., Massidda, B., Natale, D., Filippelli, G., Farris, A., Condemi, G., et al. (2009). “Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”. In Journal Clinical Oncology.

“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”

PALMERI, Sergio;
2009-01-01

Settore MED/06 - Oncologia Medica
2009
ASCO Annual Meeting
2009
1
Comella, P., Massidda, B., Natale, D., Filippelli, G., Farris, A., Condemi, G., et al. (2009). “Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”. In Journal Clinical Oncology.
Proceedings (atti dei congressi)
Comella, P; Massidda, B; Natale, D; Filippelli, G; Farris, A; Condemi, G; Palmeri, S; Tafuto, S; Vessia, G; Barberis, G
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/45274
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact